ArticleOncoTargets and therapy2022

Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine.

Lei-Si Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.